FDA Discussing Guidance On Giving Drug Economic Data To Formulary Managers
This article was originally published in The Pink Sheet Daily
FDA official Tom Abrams recently acknowledged heightened stakeholder interest in guidance on appropriate communications of health care economic data under FDAMA Sec. 114.
You may also be interested in...
Agency’s advertising office Director Tom Abrams offers hints of FDA’s thinking ahead of the infamously delayed social media guidance.
A review of FDA enforcement actions against drug marketing practices over the past 10 years finds no mention of specific violations of Sec. 114 of the FDA Modernization Act, which allows drug companies to take the initiative to disseminate health economic information to formulary managers in certain circumstances.
Study sponsored by Association for Accessible Medicines suggests quirks in Part D benefit design and rebating practices are driving the trend.